Log In
Print
BCIQ
Print
Print this Print this
 

CV9201

  Manage Alerts
Collapse Summary General Information
Company CureVac GmbH
DescriptionVaccine comprised of modified mRNA components coding for 5 different antigens frequently expressed on NSCLC cells
Molecular Target
Mechanism of ActionVaccine
Latest Stage of DevelopmentPhase I/II
IndicationNon-small cell lung cancer (NSCLC)
Partner

 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today